Roth MKM Reinstates Buy on Journey Medical, Announces $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes has reinstated a Buy rating on Journey Medical (NASDAQ:DERM) and announced an $11 price target.
June 28, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jason Wittes has reinstated a Buy rating on Journey Medical (NASDAQ:DERM) and set an $11 price target.
The reinstatement of a Buy rating and the announcement of an $11 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100